 SMC Global Securities Ltd Q2 FY2025-26 consolidated net profit declines to Rs. 20.65 crores
SMC Global Securities Ltd Q2 FY2025-26 consolidated net profit declines to Rs. 20.65 crores Rajoo Engineers Ltd Q2FY26 consolidated profit at Rs. 14.18 crores
Rajoo Engineers Ltd Q2FY26 consolidated profit at Rs. 14.18 crores Inventurus Knowledge Solutions Ltd consolidated Q2 FY2025-26 PAT climbs to Rs. 180.71 crores
Inventurus Knowledge Solutions Ltd consolidated Q2 FY2025-26 PAT climbs to Rs. 180.71 crores IFB Industries Ltd consolidated PAT for Q2FY26 jumps to Rs. 50.79 crores
IFB Industries Ltd consolidated PAT for Q2FY26 jumps to Rs. 50.79 crores Share India Securities Ltd consolidated Q2 FY26 net profit at Rs. 92.91 crores
Share India Securities Ltd consolidated Q2 FY26 net profit at Rs. 92.91 crores 
              Friday, June 19, 2009: The post lunch session on day two of Bio Bangalore 2009, India's premier Biotechnology event organized by the Department of Information Technology, Biotechnology and Science & Technology, Government of Karnataka, Vision Group on Biotechnology and MM Activ Sci-Tech Communications Co, saw medical innovation n entrepreneurial experts come together to discuss 'Cost Effective Diagnostics for India'.
The session was chaired by Dr.B.V.Ravi Kumar, MD, XCyton Diagnostics ltd.
Prof. P.V.Subba Rao from Bigtec started the session and spoke about Emerging World Diagnostics in view of lifestyle changes, Prof.Subba Rao said, "Point of care diagnostics has a major role to play as they are independent, cost effective, time saving and inexpensive." "He stressed on the fact that we need to improve on the 5Ds of death, disease, disability, discomfort and dissatisfaction through Innovative and cost effective diagnostics."
Agreeing with him, Dr.Anand Sivaraman, Sr. project leader, ReaMetrix India Pvt. Ltd. said, "The main problem of healthcare in India is that it is excessively expensive and design criteria are over-emphasized. Intensive care often becomes expensive care." Calling for optimizing the manufacturing process, he further said, "India must move towards combining innovation and solutions and moving from illness diagnosis to wellness diagnosis."
Dr. Shama Bhat, Founder, Chairman & MD, Bhat Bio-Tech India Pvt. Ltd. Said, "There exists a vast difference between the demand and supply of healthcare in India. India is home to 16% of the world's population yet, we spend only 1% of the global expenditure on health."
"The lack of hygienic conditions is the root cause for most of the diseases that affect India. He stressed on the fact that Innovation in Diagnostics should be "India's answer to its healthcare lapses and problems", added Dr. Bhat.
Dr. Sami N. Guzder, Chief Scientist, Avasthegen Ltd, concluded the session with his talk on molecular diagnostics. He said, "Molecular diagnostics will play a significant role in boosting the effectiveness of medical therapies since it diagnosis the diseases at a very early stage and thus reduce the cost quite significantly."